Wroclaw Research Centre EIT+ Ltd

Mirosław Miller

Wroclaw in nutshell

• Fourth largest city in Poland • Second highest budget • 1 million people • Lower Silesia region: 3 million • 11 universities • 140,000 students • 11,000 scientists • 5 billion EUR investment 2003-2010

Knowledge Based Economy Regionally – Wroclaw concept

1. Skilled people needed 2. Innovation supporting ecosystem incl. open infrastructure dedicated to innovation projects 3. Effective collaboration between academia – innovative industry 4. Local and central government support (incl. financial) 5. Trust between KBE actors: research - business 6. Financing available (from seed to venture) 7. Transfer of the best practices

Regional Strategy for Lower Silesia 2007 - 2013

The

EIT+

programme

Investing substantial portion of the EU-based structural and cohesion funds into:  Making Lower Silesia the European Knowledge Region in the European Research Area (ERA)  Making material conditions for strong partnership between Higher Education, Research and Innovative Business & Economy  Making Lower Silesia a knowledge-based economy region

Academia Europaea in London and Wroclaw

Founded in 1988, with over 2000 members which includes leading experts from the physical sciences and technology, biological sciences and medicine, mathematics, the letters and humanities, social and cognitive sciences, economics and the law.

Wroclaw Research Centre EIT+

Shareholders

Wroclaw University of Technology University of Wroclaw Wroclaw Medical University Wroclaw University of Environmental and Life Sciences Wroclaw University of Economics Concept Lower Silesia Region

EIT+ Strategy

Maximum use of Structure Fond for the development of the Company and core competences The broad international presence (6 of the most innovative countries) Fast development of commercialisation and marketing department, acquisition of key customers The development of a portfolio of business projects with private partners from R&D and innovative economy sectors

Research areas: convergence technologies

Life Sciences Nanotechnology Climate and Energy ICT technologies

Key EIT+ projects financed from IE OP

NanoMat 31.1 m Euro Pracze Campus 140 m Euro BioMed 27.6 m Euro

City of Wrocław Climate EIT 300 T Euro ICT, 7 FP 2,5 m Euro IBM Fraunhofer EADS KGHM Accelerator spin-off 3 m Euro

Research and technology projects – role of EIT+

• Initiation of project (identification of real innovation needs) • Looking for business partner • Looking for research partner • Defining the financial model • Preparation of project application • Project management / coordination / administration • Key scientists responsible for the research area • Monitoring / reporting • Commercialization (IP management) •

After 2013: operation of the own infrastructure open for projets not for institution

Demand analysis

80% of R&D and co-development deals made by the top 10 pharma companies were with biotech and small pharma companies, with 7% attributed to partnerships with universities and academic institutions 1 . Market analysis 2. Research potential in Poland 3. Analysis of potential patrners

Market analysis

Areas of analysis Questions to analysis

The world-leading provider of premium Pharmaceutical & Healthcare and Retail industries.

global business information, delivering independent data, analysis and opinion in The most comprehensive database of private and public biomedical companies. We are searching pipeline, financial, competitive products, deals, mechanism of action, partnering, and patent information on biomedical companies, and products worldwide.

10 top pharma companies (Novartis, Elli Lilly etc), generic companies, emerging markets, mature markets, R&D strategies • • Market trends with particular emphasis on the need for research and biotechnology products Analysis of the activities of pharmaceutical companies and their demand for innovative R&D • Companies producing original drugs • Companies producing generic drugs

Market analysis – areas and questions

General Issues: Global biotechnology, Global venture capital insights and trends, Global pharmaceutical industry, New Approaches to Pharma R&D, Future Pharmaceutical Industry Trends, Licensing Strategy Update year in review Emerging Markets: Brazil, India, Russia, China, Top Pharma Players: Bayer AG, ,Boehringer Ingelheim GmbH, Merck & Co., Inc., Eli Lilly & Co., Pfizer Inc., J&J, Astra Zeneca, Hoffman-La Roche, GSK, Novartis, Sanofi-Aventis, Biologics:Merck KgA, Amgen, Teva Pharma 1.

Prescription pharmaceutical sales and growth rate performance ?

2 Financial performance?

3. Strategic insight key developments 4. SWOT analysis 5. Current corporate structure 6. M&A history 7.Product analysis 8. Launch/core/expiry analysis 9. Key products 1. Demographic trends 2. Political climate 3. Economic climate 4. Business environment 5. Healthcare expenditure 6. Healthcare system 7. Regulatory issues 8. Pricing and reimbursement 9. Generics market dynamics 10. Key generics players and pharmaceutical industry infrastructure overview

Commercialisation models

Key competence of EIT+ • Spin-off technology companies • Licensing • Project implementation in partnership with business (Academia to Business Forum)

„Innovation funnel”

Creating – investing in spin-off companies

EIT+ role in financing an early stage of R&D projects

Private Equity Stock Exchange

FORUM A2B

Seed Capital Business Angels

Spin off Accelerator GIZA POLAND VC

Venture Capital years

Pracze Campus today…

BLDG 9: BIOTECHNOLOGY LABORATORIES BLDG 7: BIOTECHNOLOGY AND NANOTECHNOLOGY LABORATORIES 17 BLDG1 B, C: MATERIALS CHARACTERISATION LABORATORIES BLDG 9 A: CHEMICAL SYNTHESIS AND NANOTECHNOLOGY LABORATORIES

EIT+ laboratories

• 34 research and technology laboratories of the total space over 24,000 m2: materials science, life sciences, medicine • 23 laboratories unique for Poland (GLP, GMP, BSL3 standards). • Multidisciplinary research centre of unique infrastructure for Wroclaw • 90 work places for people of high qualifications

Pracze Campus – basic concept

• open research infrastructure: project oriented (not institution oriented) • “critical mass” of the skilled people and R&D investors • “random meeting places” for: - creative and ambitious researchers and entrepreneurs - specialists of different expertise - local scientists and guest scientists visiting Pracze Campus - young and experienced scientists and industry partners • easily accessible for scientists and entrepreneurs • operated by the dedicated, market oriented company (EIT+) • financed by the projects realized in laboratories • additional expertise of importance: IP management, spin-offs establishing, marketing of research, patenting, project management, technology and capital funds

Wrocław „innovation pole” in Pracze

R&D investment area I R&D investment area II R&D investment area III

Pracze Campus today…

Pracze Campus in 2013

Pracze Campus in 2020

Wrocław Innovation Hub

EIT+ faces

EIT+ faces

Prof. dr. hab. Detlef Hommel

The

NanoMat

project coordinator

Prof. dr. hab. Jacek Otlewski

The

BioMed

project coordinator

EIT+ faces

Dr. Magdalena Ornatowska

Life Science Department

Dr.

Łukasz Nieradko

Nanotechnology Department

EIT+ faces

Dr.

Radosław Piesiewicz

ICT Department

Cezary Lejkowski

Climate and Energy Department

EIT+ and polish diaspora

Tomasz Mroczkowski

American University WASHINGTON

Oskar Zięta

ETH Zurich SWITZERLAN BREMEN ZURICH

Anna Topol

IBM Research NEW YORK

Prof. Andrzej Pawlak Janusz Liberkowski

USA

Karol Kozak

ETH Zurich SWITZERLAN

Dr Ami B. Friedman

MATIMOP OCS IZRAEL

Siew Hwa ONG, PhD

Director & Chief Scientist at Acumen Research Laboratories Pte Ltd, SINGAPUR

Dr Donald Wlodkowic

The BioMEMS Research Group NEW ZEALAND

Thank you

www.eitplus.pl